Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial

详细信息    查看全文

• 作者：Gaë ; l Deplanque ; MD ; PhD^a ; ^{gael.deplanque@chuv.ch" class="auth_mail" title="E-mail the corresponding author} ; Radj Gervais ; MD^b ; Alain Vergnenegre ; MD ; PhD^c ; Lionel Falchero ; MD^d ; Pierre-Jean Souquet ; MD^e ; Jean-Michel Chavaillon ; MD^f ; Bruno Taviot ; MD^g ; Ghislaine Fraboulet ; MD^h ; Hakim Saal ; MDⁱ ; Caroline Robert ; MD ; PhD^j ; Olivier Chosidow ; MD ; PhD^k ; on behalf of CYTAR investigators
• 关键词：doxycycline ; erlotinib ; folliculitis ; non-small-cell lung cancer ; rash
• 刊名：Journal of the American Academy of Dermatology
• 出版年：2016
• 出版时间：June 2016
• 年：2016
• 卷：74
• 期：6
• 页码：1077-1085
• 全文大小：573 K

文摘

Rash is a common epidermal growth factor receptor inhibitor–induced toxicity that can impair quality of life and treatment compliance.

c_2">Objective

We sought to evaluate the efficacy of doxycycline in preventing erlotinib-induced rash (folliculitis) in patients with non-small-cell lung cancer.

c_3">Methods

This open-label, randomized, prospective, phase II trial was conducted in 147 patients with locally advanced or metastatic non-small-cell lung cancer progressing after first-line chemotherapy, randomized for 4 months with erlotinib alone 150 mg/d per os (control arm) or combined with doxycycline 100 mg/d (doxycycline arm). Incidence and severity of rash, compliance, survival, and safety were assessed.

c_4">Results

Baseline characteristics of the 147 patients were well balanced in the intent-to-treat population. Folliculitis occurred in 71% of patients in the doxycycline arm and 81% in the control arm (P = .175). The severity of folliculitis and other skin lesions was lower in the doxycycline arm compared with the control arm. Other adverse events were reported at a similar frequency across arms. There was no significant difference in survival between treatment arms.

c_5">Limitations

The open-label design of the study and the duration of the treatment with doxycycline are limitations.

c_6">Conclusion

Doxycycline did not reduce the incidence of erlotinib-induced folliculitis, but significantly reduced its severity.